Moon, C. Y. et al. Dendritic cell maturation in most cancers. Nat. Rev. Most cancers 25, 225–248 (2025).
You, Q. et al. A nanovaccine concentrating on most cancers stem cells and bulk most cancers cells for postoperative most cancers immunotherapy. Nat. Nanotechnol. 20, 1298–1311 (2025).
Zhou, J. et al. STAT5 and STAT3 stability shapes dendritic cell perform and tumour immunity. Nature 643, 519–528 (2025).
Shapir Itai, Y. et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell 187, 375–389.e318 (2024).
Eweje, F. et al. Self-assembling protein nanoparticles for cytosolic supply of nucleic acids and proteins. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02664-2 (2025).
Meiser, P. et al. A definite stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protecting anti-cancer immunity. Most cancers Cell 41, 1498–1515.e1410 (2023).
Plebanek, M. P. et al. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes most cancers development. Sci. Immunol. 9, eadi4191 (2024).
Calzada-Fraile, D. et al. Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for environment friendly priming of CD8+T cells. Nat. Commun. 14, 6772 (2023).
Jacobs, C. F. et al. Ldl cholesterol homeostasis and lipid raft dynamics on the foundation of tumor-induced immune dysfunction in power lymphocytic leukemia. Cell Mol. Immunol. 22, 485–500 (2025).
Lei, Ok. et al. Most cancers-cell stiffening through ldl cholesterol depletion enhances adoptive T-cell immunotherapy. Nat. Biomed. Eng. 5, 1411–1425 (2021).
Xiao, J. et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to teach immunosuppressive macrophages. Immunity 57, 1087–1104.e1087 (2024).
Kropshofer, H. et al. Tetraspan microdomains distinct from lipid rafts enrich choose peptide-MHC class II complexes. Nat. Immunol. 3, 61–68 (2002).
Geels, S. N. et al. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Most cancers Cell 42, 1051–1066.e1057 (2024).
Molino, N. M., Anderson, A. Ok., Nelson, E. L. & Wang, S. W. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano 7, 9743–9752 (2013).
Rosalia, R. A. et al. Dendritic cells course of artificial lengthy peptides higher than complete protein, bettering antigen presentation and T-cell activation. Eur. J. Immunol. 43, 2554–2565 (2013).
Belabed, M. et al. Ldl cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to most cancers. Nat. Immunol. 26, 188–199 (2025).
Li, B. et al. Fueling sentinel node through reshaping cytotoxic T lymphocytes with a flex-patch for post-operative immuno-adjuvant remedy. Nat. Commun. 14, 2518 (2023).
Shapiro, I. E. & Bassani-Sternberg, M. The impression of immunopeptidomics: from fundamental analysis to medical implementation. Semin. Immunol. 66, 101727 (2023).
Zeng, B. et al. Self-adjuvanting nanoemulsion concentrating on dendritic cell receptor Clec9A allows antigen-specific immunotherapy. J. Clin. Make investments. 128, 1971–1984 (2018).
Zhang, J. et al. Stimuli-responsive nanoparticles for managed drug supply in synergistic most cancers immunotherapy. Adv. Sci. 9, e2103444 (2022).
Cruz, L. J. et al. Focusing on nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for environment friendly CD8+ T cell response: a comparative examine. J. Management. Launch 192, 209–218 (2014).
